Navigation Links
aTyr Pharma Appoints Catharine E. Johnson As Senior Vice President of Business Development

SAN DIEGO, June 14 /PRNewswire/ -- aTyr Pharma, Inc. today announced that Catharine E. Johnson, Ph.D. has recently joined the company as its Senior Vice President of Business Development.  Dr. Johnson's extensive biotechnology industry experience will help to advance aTyr Pharma's portfolio of resectin-based therapeutics. Resectins are a novel class of endogenous human proteins derived from aminoacyl tRNA synthetases, and have activities relevant to multiple disease areas, including autoimmunity, inflammation, and blood disorders. The privately held biotech was co-founded by Dr. Xianglei Yang and Dr. Paul Schimmel, a leading aminoacyl tRNA synthetase scientist and serial entrepreneur in the biotech sector.

Dr. Johnson brings a broad range of strategy and business development experience to aTyr. She was most recently Vice President, Corporate Development at Momenta Pharmaceuticals, Inc. (MNTA), where she managed corporate strategy and negotiated transactions related to the company's proprietary technology platform and product portfolio, including significant transactions with Novartis AG/Sandoz.  Dr. Johnson was previously a Principal at Atlas Venture, where she was responsible for new biotech investments and the management of portfolio companies.  She also served as head of business development at Regeneron Pharmaceuticals, where she was responsible for new business initiatives, strategic partnering, and alliance management, and her activities included key transactions with Novartis, Aventis, and Serono.  Dr. Johnson received her Doctorate from the Johns Hopkins School of Medicine's Department of Biological Chemistry.

"Catharine is an important addition to our senior management team," said Jeff Watkins, aTyr Pharma's Chief Executive Officer, adding "She brings extensive expertise in a variety of functions essential for building a strong and sustainable biotech company, and will bring substantial value to aTyr as we build our product portfolio and select strategic partners."

"Resectins are an enormous opportunity for the development of new medicines, and it is a privilege to be a part of such promising new science.  I am excited to work along side such a talented and committed management team, backed by experienced investors and successful scientific founders," said Dr. Johnson.  "Overlooked by the human genomics efforts, and with activities that are differentiated from existing therapies and common pharmaceutical discovery targets, the resectins represent a wealth of completely novel product opportunities.  The establishment of a select set of strategic partnerships will be a significant catalyst for aTyr's growth, and will enable the company to fully capture the value underlying aTyr's novel source of the resectin human proteins and drug targets."

About aTyr Pharma

aTyr Pharma engages in the generation of innovative therapeutics based on a new class of naturally occurring human proteins.  These proteins, called resectins, modulate extracellular signaling pathways in a variety of biological processes.  Resectins, previously overlooked by genomic efforts due to their hidden intra-protein location in ancient aminoacyl tRNA synthetase genes, have recently been discovered by aTyr, which is leading to connections in human physiology and pathophysiology ranging from inflammation to metabolic disease to peripheral neuropathy to blood disorders.  Resectin biology is distinct from currently known pathways and pharmaceutical targets and thus represents breakthrough opportunities for novel therapeutic interventions.  Tmax, aTyr's first program, is a preclinical replacement protein candidate with a novel thrombopoietic activity for the treatment of thrombocytopenia.  aTyr Pharma has established a dominant intellectual property estate surrounding resectin based compositions and therapeutic applications.

The privately held biotech was founded by Dr. Paul Schimmel, a leading aminoacyl tRNA synthetase scientist and biotechnology entrepreneur who is also a founder of Alkermes (ALKS), Cubist (CBST), Alnylam (ALNY), Sirtris (acquired by GlaxoSmithKline, GSK), Momenta Pharmaceuticals (MNTA), and Repligen (RGEN), and a founding SAB member of Illumina (ILMN). aTyr Pharma is backed by leading life sciences investors Alta Partners, Cardinal Partners, and Polaris Ventures.  For more information please visit

SOURCE aTyr Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmatech Oncology to Present at 46th Annual DIA Meeting
2. Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
3. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
4. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
5. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
6. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
7. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
8. Diplomat Specialty Pharmacy Launches New Navigator Health Services to Meet Next Generation Needs of Specialty Pharmacy Industry
9. BioMed Realty Trust Breaks Ground on 176,000 Square Foot R&D Facility for Isis Pharmaceuticals in Carlsbad, California
10. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
11. University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses
Post Your Comments:
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
Breaking Biology Technology:
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
Breaking Biology News(10 mins):